X

Trial Profile

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 May 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PAC 1 (Primary) ; Temozolomide (Primary)
Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Acronyms Component 2
Sponsors Vanquish Oncology

Most Recent Events

22 May 2023 Status changed from suspended to discontinued.
18 Sep 2020 Planned End Date changed from 30 Jun 2020 to 30 Jun 2022.
18 Sep 2020 Planned primary completion date changed from 30 Dec 2019 to 31 Dec 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com